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INTRODUCTIONANDAIMS:Delayed graft function (DGF) negatively impacts on
kidney transplant (KT) outcomes. This study aimed to assess the impact of pulsatile
machine perfusion (MP) in kidney transplants performed in a Brazilian region where
transplants with standard criteria donors are predominant.
METHODS: Prospective cohort including 180 KT performed from Jan/15 to Jul/17,
who received paired kidneys from 90 deceased donors in which one underwentMP fol-
lowing static cold storage (CS) preservation (MP group) and the other underwent only
static cold storage (CS Group). The decision forMP or CS was at discretion of trans-
plant staff. The primary end-point was DGF incidence (requirement for dialysis in the
first week after KT) and duration.
RESULTS:Donors were young (31613 years), mixed race (80%), non-hypertensive
(97%), non diabetic (100%), overweigh (BMI 2664kg/m2), who died due to traumatic
brain injury (71%), with final serum creatinine of 1.360.7mg/dL. 95%were standard
criteria donors and the mean KDPI and KDRI were 32621% and 0.8660.2, respec-
tively. Custodiol HTK was the solution used in 84% immediately after harvest surgery.
There were no differences between groups. Demographic characteristics of the KT
recipients were similar in both groups: males (60%), young (41618 years), mixed race
(86%), with chronic kidney disease of unknown etiology (38%), and 45645months on
dialysis. However, patients onMP group were more sensitized: panel reactive antibod-
ies (PRA) 18630 vs. 13628% and pre-transplant donor specific antibodies (DSA) 17
vs. 3% (p¼0.005). The total cold ischemia time (TIF) was 2966 vs. 2164h (p<0.001),
and dynamic CIT was 1366h. MP significantly reduced the incidence of DGF (30 vs.
53%, p¼0.002), and there was no difference on time on DGF (16620 vs. 13618 days,
p¼0.516).
CONCLUSIONS:Despite higher immunological risk, patients who receivedMP kid-
neys presented lower incidence of DGF. This cohort will be followed to assess the
impact of DGF reduction on long-term outcomes.
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INTRODUCTIONANDAIMS: Kidney transplantation is the most preferred treat-
ment modality for end-stage renal disease (ESRD). The success of transplantation pro-
grams depend on knowledge, awareness and attitude. Our aims were to assess the
knowledge and attitude of the people, including physicians and other health care
related professionals (HCPs) about ESRD, its treatment options and their views
towards kidney transplantation.
METHODS: This cross-sectional survey was conducted from July 2015 to June 2017
among trainee physicians and other HCPs of four tertiary care hospitals and adult peo-
ple seeking general health care services as outpatients in three rural areas of Bangladesh.
Data were recorded in preformed semi-structured forms and analyzed accordingly.
RESULTS: Among the 3000 participants, physicians were 21%, other HCPs 28.5% and
general people 50.5%with a female predominance (M:F¼1:1.2). Most of the partici-
pants were from urban areas (79%) and with an educational background of higher sec-
ondary (HSC) or above (65%). Overall 72% (n¼2160) had knowledge about ESRD
and its treatment options. About 89% of them responded that kidney transplantation is
the best treatment option especially living related donor renal transplant (LRDT, 60%).
Chance of better function and survival of donated kidney (43.8%) and easy to convince
both the recipient and donor (37.5%) was marked by the participants as the benefit of
LRDT. Unavailability of suitable donor (70.8%) was marked as the main disadvantage
of LRDT. Only 1500 of 2160 (69.4%) participants agreed to donate kidney but 60% had
fear of developing renal failure after donation and 50% thought that the other family
members will not cooperate. They had positive view (77.1%) for cadaveric or deceased
donor kidney transplant. But 68.1% thought that the concept of cadaveric kidney dona-
tion is still not well accepted and 72.2% believe that there is religious barrier. There was
no significant difference of opinions between the physicians with other HPCs or, with
general people except regarding motivation of kidney donation (physicians vs other
HCPs: p¼0.000 and physicians vs general people: p¼0.000). The rural peoples’ knowl-
edge regarding ESRD and treatment options were significantly (p¼0.000) less than the
urban peoples and also significantly (p¼0.000) less motivated for kidney donation and
deceased donor kidney transplantation. The awareness about ESRD, its treatment and
motivation for kidney donation was significantly less (p¼0.000) among the
respondents with educational background of less thanHSC and there is also significant
difference (p¼0.003) of opinion regarding deceased donor kidney transplantation
among the persons with higher educational background.
CONCLUSIONS: In spite of reasonable awareness level about ESRD, kidney transplan-
tation and donation, a high proportion of the participants did not have positive atti-
tudes towards kidney donation. Themisconception and fear about kidney
transplantation and donation has to be addressed to continue a successful kidney trans-
plant program in a developing country like Bangladesh.
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INTRODUCTIONANDAIMS: The immune system is directly involved in the patho-
genesis of atherosclerosis and coronary artery disease but its role in cardiovascular dis-
ease after transplantation remains uncertain. The negative role of especially class II
donor specific antibodies (DSA) on kidney graft outcome is well-recognized. Recently,
high panel reactive antibodies (PRA) at the time of transplantation and class II DSA 6
months post transplantation were associated with worse cardiovascular outcome in
kidney transplant recipients. Our hypothesis was that pre-formedHLA class II antibod-
ies at the time of transplantation were associated with worse cardiovascular outcome
after kidney transplantation.
METHODS:We conducted a single-center, observational retrospective cohort study
including 1114 kidney transplant recipients transplanted between January 2003 and
December 2016. Data on the presence of HLA class II antibodies at the time of trans-
plantation were available in 827 subjects. The primary outcome of interest was a com-
posite of time tomajor adverse cardiac and cerebrovascular events and all-cause
mortality (MACCE) with up to 15 year follow-up. Secondary outcomes were a compo-
site of cardiac and cerebrovascular events with or without cardiovascular mortality. We
designed amultivariable Cox proportional hazard regressionmodel with adjustment
for potential confounders including age, sex, PRA and re-transplantation as well as for
polyclonal induction, diabetes and baseline cardiovascular disease at time of transplan-
tation.We registered the incidence of biopsy proven acute rejection (BPAR) and graft
loss for separate subgroup analysis.
RESULTS: Themean age of the patients (62%male) was 52 (613) years with amean
follow-up of 5.4 (63.3) years. One hundred and sixteen patients (14%) had HLA class
II antibodies at the time of transplantation. Sixty-seven patients (8.1%) received poly-
clonal antibodies as induction therapy. BPAR occurred in 120 patients (14.7%) and
graft loss in 59 patients (7.3%) with no statistical difference in incidence between
patients with or without class II HLA antibodies. Seventy-eight patients (9.7%) had
adverse cardiac and cerebrovascular events and 83 (10%) died during follow-up. The
primary outcome analysis revealed an adjusted hazard ratio (aHR) ofMACCE in those
with versus without class II HLA antibodies of 1.71 (95%CI of 1.13 to 2.60). The
increased aHR due to class II HLA positivity was confirmed in a subgroup analysis in
patients without BPAR or graft loss with an aHR of respectively 2.03 (95%CI of 1.29 to
3.18) and 1.97 (95%CI of 1.25 to 3.12). The secondary outcome analysis showed an
aHR of 1.92 (95%CI of 1.11 to 3.3) and an aHR of 1.85 (95%CI 1.06-3.2) for cardiac
and cerebrovascular events respectively with and without cardiovascular mortality.
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CONCLUSIONS: Previous sensitization against HLA class II antigens is associated
with unfavorable long-term cardiovascular outcome in kidney transplant recipients
independent of effects on graft function.
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INTRODUCTIONANDAIMS:Controlled donation after circulatory death (cDCD)
programs are running in some European countries. Spanish National transplant organ-
ization (ONT) has developed a nationwide program from jan-2012 and 45 Centers had
progressively joined by Dec2016 (1437 cDCDKidney transplants-KTx). 22 centers
have entered our study group.We present here subanalysis for the impact of DGF on
the best eGFR.
METHODS: Study: prospective multicentre. Systematic inclusion of every KTx from
cDCD at joined units. Local center surgical procedures and IS protocols.
RESULTS:Our DB included 614 ESRD patients who received a Graft from cDCD,
donors (died mainly due to CV events). 52.1 % presented delayed graft function
(DGF), 4,7% early graft failure (PNFþ 1st month graft failure), 7.8% returned to dialy-
sis and 4.7% died on amean follow-up of 2.4 years. We excluded 111 patients with a
graft follow-up under 1 year. Finally 474 recipients who exceed 1st year with a function-
ing graft were included (57,2 y [19-83], 62,5%males).Immunosupressive regimen (IS)
included 98,8% induction (Thymoglobulin 67,1%/Basiliximab 32,3) plus prednisone-
MMF-Tacrolimus (83,1%) or mTOR (6,9%).Median Cold ischemia time (CIT) was
12,1h and warm IT 25min. Median HLA-mismatch was 4 [0-5]. Best eGFR after at least
1 year was 47.7ml/min, and 64%were unable to reach their best eGFR over 50ml/min.
Main characteristic of both groups are summarized on Table 1.
Risk factors associated to best eGFR below 50ml/min (Logistic Regression)
eGFR
50 ml/
min
eGFR
<50 ml/
min
p OR
Multivariate
for eGFR
< 50 ml/min
DONOR
Age (years, mean (SD)) 52.8 (12.3) 59.4 (11.1) <0.001 1.20 [1.07-1.34]
per 5y
Gender (male, %) 66.3 67.1 NS
HTA (%) 33.9 42.6 0.07
DM (%) 9.3 16.2 0.09
RECIPIENT
Age (years, mean (SD)) 51.6 (12.4) 57.6 (11.0) <0.001 1.11 [1.00-1.24]
per 5y
Gender (male, %) 50.3 78.9 <0.001 3.82 [ 2.45-5.94]
Diabetes Mell. (%) 25.5 31.1 0.3
Previous CV event (%) 10.3 11.6 NS
TRANSPLANT
DGF 38.8 60.4 <0.001 1.97 [1.29-3.01]
HLA (missmatch) 3.97 (1.21) 3.92 (1.34) NS
Baxilisimab(%)
vs Timoglobulin
27.3 34.0 0.06
Risk factor univariate analysis for best eGFR under 50ml/min includes: Older andmale
donor and recipients, comorbidity, IS (Baxilisimab vs Thymoglobulin) or DGF vs
immediate function. Best Multivariate logistic regression model got an r-value of 0,39
and includes only DGF corrected by Donor Age and Recipient Age and Sex. (Table 1)
CONCLUSIONS:KTx with cDCD present higher DGF than historic reference for brain
death donors. DGF associates worst 1st year eGFR, although have no impact on Graft or
patient survival.
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INTRODUCTIONANDAIMS: Transplant physicians increasingly face the dilemma
of accepting or rejecting kidney offers that are less than optimal. Predictive scoring
tools that maximize organ utilization without compromising outcomes are needed. For
the US organ allocation system the kidney donor profile index (KDPI) has been devel-
oped to rank donor kidney quality in relation to long-term allograft survival. We have
assessed the KDPI in relation to outcomemarkers of early kidney graft function.
METHODS: In a retrospective study the KDPI score was calculated using the following
donors’ characteristics: age, height, weight, ethnicity, history of hypertension, history
of diabetes, cause of death, serum creatinine, HCV status and DCD criteria. All adult
patients who received a deceased donor kidney in the year 2017 in our center were
included. As outcome markers for early kidney function were analyzed: (a) need for
dialysis, i.e. delayed vs. immediate graft function (DGF vs. IGF), (b) fall in creatinine
from postoperative day 1 to day 2 (CRR2), (c) lowest observed serum creatinine during
the first postoperative month (LoObsSCr_Mo1), and (d) difference between observed
and expected serum creatinine (D obs vs. exp). Data were analyzed by descriptive statis-
tics with p-values<0.05 considered as statistically significant.
RESULTS:Of the total of 74 adult kidney transplants 27%were DCD organs, 63% of
all showed IGF and 37%DGF, requiring at least one postoperative dialysis treatment.
(a) The mean KDPI was 51% for all deceased donor kidneys, 44% for kidneys trans-
planted to recipients with IGF and 63% for those with DGF, the difference being statis-
tically significant (p<0.01). (b) KDPI did not correlate with the earliest creatinine fall
(CRR2, p¼0.09), however a trend towards a higher fall in organs with a low (<20%) vs.
moderate (20 to 85%) vs. high KDPI (>85%) was seen. (c) The lowest KDPI organs
showed the best creatinine values in the first month (LoObsSCr_Mo1, r¼0.6,
p<0.001). (d) In the patients who received the organs with the highest KDPI (>85%)
the difference between observed and expected creatinine levels was significantly higher
than in those with KDPI organs<85% (D obs vs. exp of 64 vs. 35 umol/l). In contrast to
the KDPI scores donor demographic data alone did not differentiate the various early.
CONCLUSIONS: The KDPI score is associated with early post-transplant kidney graft
function and is useful to capture kidney organ quality, i.e. nephronmass and regenera-
tive capacity.
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INTRODUCTIONANDAIMS: Selection using epitope mismatches (EpMM) has
good potential in recipients with pre-existing antibodies, and also in kidney allocation
in network of transplant centres with a large common waiting list. In Russia, every
transplant center has its own separate waiting list. Is the use of EpMM advantageous
compared to the use of broad antigen mismatches (BAMM) in a single transplant
centre?
METHODS:We perform the retrospective single-center study to research the link
between the risk of graft loss and number of EpMM.We included 789 adult recipients
of cadaveric kidney graft (AB0 compatible only). HLA-genotyping (A, B, DR loci) was
performed in all cases. Median follow-up was 8.1 (IQR 4.8; 10.4) years. We used a
Poisson regression to estimate the risk of graft loss.
RESULTS: In most cases (54%) the transplantation was performed with 3-4 BAMM.
Survival analysis showed a higher number of BAMM to be associated with an increased
risk of graft loss (log rank p<0,001) (fig. 1).Each HLAmolecule has a unique set of epit-
opes. The number of EpMMhas wide range even in a fixed value of BAMM. This sug-
gests that recipients with the same number of BAMM can differ significantly in their
compatibility with the graft on epitope level (fig. 2).Even after the adjustment for num-
ber of BAMM and other factors, the increasing of number of EpMMwas significantly
associated with increase of graft loss incidence rate ratio, as well as de novoDSA cumu-
lative incidence (fig. 3).So, for example, in a case of 4 BAMM (N¼249, 31.6% of cases)
the median number of EpMMwas 24 (IQR 20-30, min-max 10-43).We noted signifi-
cant difference in survival rate between patients with 10-24 and 25-43 EpMM
(p¼0.012) (fig. 4). EpMM allow for more accurate prediction of the risk of graft loss:
the area under the ROC curve was 0,812 [0,766; 0,858] vs. 0,649 [0,59; 0,707] in BA
MM. This approach allows to identify patients at high risk of graft loss (over 20 EpMM)
amongst patients, who were previously considered to have low immunological risk (i.e.
1-2 BAMM). In our analysis we considered the transplantations, which was performed
in 1994-2016. Immunosuppressive therapy during this period has changed signifi-
cantly. Curiously, the five-year periods of transplantation is a significant predictor of
long-term graft survival in multivariate models with BAMM (the significance of the
immune factor gradually decreases with time), but is insignificant in the model with
EpMM.
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